Fluparoxan

Fluparoxan

Fluparoxan is a drug that was developed by GlaxoSmithKline for the treatment of depression and anxiety. It is classified as a selective alpha-2 adrenergic receptor antagonist, which means it works by blocking the action of certain neurotransmitters in the brain.

History

Fluparoxan was first synthesized in the late 1980s by researchers at GlaxoSmithKline. It was initially developed as a potential treatment for depression and anxiety, but its development was discontinued in the early 1990s due to lack of efficacy in clinical trials.

Pharmacology

Fluparoxan is a selective alpha-2 adrenergic receptor antagonist. This means it works by blocking the action of norepinephrine and epinephrine at alpha-2 adrenergic receptors in the brain. These receptors are involved in regulating mood and anxiety, and by blocking their action, Fluparoxan is thought to alleviate symptoms of depression and anxiety.

Clinical Trials

Several clinical trials were conducted to assess the efficacy of Fluparoxan in the treatment of depression and anxiety. However, the results were not promising, and the development of the drug was discontinued in the early 1990s.

Side Effects

Like all drugs, Fluparoxan has the potential to cause side effects. These can include nausea, dizziness, and insomnia. However, due to the discontinuation of its development, the full range of potential side effects is not known.

Current Status

As of now, Fluparoxan is not approved for use in any country. Its development was discontinued in the early 1990s due to lack of efficacy in clinical trials.